MiNK Therapeutics, Inc. (INKT)

Market Cap	27.87M
Revenue (ttm)	n/a
Net Income (ttm)	-17.09M
Shares Out	39.54M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,658
Open	0.690
Previous Close	0.687
Day's Range	0.678 - 0.715
52-Week Range	0.570 - 1.900
Beta	0.05
Analysts	Strong Buy
Price Target	6.50 (+822.12%)
Earnings Date	Nov 14, 2024

About INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2021
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: INKT
• Website: https://minktherapeutics.com

Analyst Forecast

According to 2 analysts, the average rating for INKT stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 822.12% from the latest price.

Price Target

$6.5

(822.12% upside)

Analyst Consensus: Strong Buy